SavedAdd your journal

Journals / İstanbul Medical Journal / 2019 / Cilt: 20 - Sayı: 6

The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients

Periton Diyaliz Hastalarında Eritropoietin Stimüle Eden Ajanlar Kullanımının Trombosit Agregasyonu Üzerindeki Etkisi

Sibel GÖKÇAY BEK
Sara YAVUZ
Necmi EREN
Serkan BAKIRDÖĞEN
Pages
524–527
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results wereevaluated statistically, and p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Erythropoietin (Epo) is a hormone thatis synthesized in the kidneys and that stimulates theerythropoiesis in the bone marrow.
📊
Key Findings & Data:In chronic renal failure (CRF) patients,hemorrhagic diathesis is observed, and Epo production isdecreased.
💡
Conclusion & Impact:The results wereevaluated statistically, and p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Erythropoietin (Epo) is a hormone thatis synthesized in the kidneys and that stimulates theerythropoiesis in the bone marrow. Epo has effects apart fromthe erythropoiesis. In chronic renal failure (CRF) patients,hemorrhagic diathesis is observed, and Epo production isdecreased. Erythropoiesis-stimulating agents (ESAs) are widelyused in the treatment of renal anemia in these patients. Ourstudy aimed to investigate the effect of ESAs use on plateletaggregation in peritoneal dialysis (PD) patients due to CRF.Methods: Forty-three PD patients were included in the study.Seventeen patients had been using ESAs for anemia for atleast three months (ESAs user group). Twenty-six patientswere not using ESAs since they did not have indications (non-ESAs user group). Platelet aggregation measurement from thewhole blood was carried out in each patient by a multiplatedevice. The calculated values [area under the curve (AUC),aggregation, and velocity] were recorded. The results wereevaluated statistically, and p

Özet

Amaç: Eritropoietin (Epo), böbrekler tarafından sentez edilen ve kemik iliğinde eritropoezi uyaran bir hormondur. Epo hormonunun eritropoez dışında etkileri de mevcuttur. Kronik böbrek yetmezliği (KBY) hastalarında kanama diyatezi görülür ve Epo üretimi azalmıştır. Bu hastalarda renal aneminin tedavisinde eritropoietin stimüle eden ajanların (ESAs) kullanımı yaygındır. Çalışmamızın amacı; KBY nedeniyle periton diyalizi (PD) uygulayan hastalarda, ESAs kullanımının trombosit agregasyonu üzerindeki etkisini araştırmaktı. Yöntemler: Çalışmaya 43 PD hastası dahil edildi. En az üç ay süreyle ve anemi nedeniyle ESAs kullanımı olan 17 hasta mevcuttu (ESAs kullanan grup). Endikasyonu olmadığından 26 hasta ESAs kullanmıyordu (ESAs kullanmayan grup). Multiplate cihazı ile her hastanın tam kandan trombosit agregasyon ölçümü yapıldı. Hesaplanan değerler [eğrinin altında kolon olan (AUC) agregasyon ve velozite] kaydedildi. Sonuçlar istatistiksel olarak değerlendirildi. P

🔖

Cite This Article

BEK, S. G., YAVUZ, S., EREN, N., BAKIRDÖĞEN, S. (2022). The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients. İstanbul Medical Journal, Cilt: 20 - Sayı: 6, 524–527. https://ajindex.com/articles/551958

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004; 43: 649- 59
  2. Lappin TR, Maxwell AP, Johnston PG. EPO’s alter ego: erythropoietin has multiple actions. Stem Cells 2002; 20: 485-92
  3. Zhou XJ, Vaziri ND. Defective calcium signaling in ureamic platelets and its amelioration with long-term erythropoietin therapy. Nephrol Dial Transplant 2002; 17: 992-7
  4. Hörl WH. Other Blood and Immune Disorders in Chronic Kidney Disease. Floege J, Johnson RJ, Feehally J, editors. Comprehensive Clinical Nephrology Fourth Edition. St.Louis, Missouri: Elsevier Saunders; 2010.p.959-68
  5. Hörl WH. [Thrombocytopathy and blood complications in uremia]. Wien Klin Wochenschr 2006; 118: 134-50
  6. Kirkeby A, Torup L, Bochsen L, Kjalke M, Abel K, Theilgaard-Monch K, et al. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 2008; 99: 720-8
  7. Borawski J, Pawlak K, Mysliwiec M. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients. Nephron 2002; 91: 671-81
  8. Würtz M, Hvas AM, Kristensen SD, Grove EL. Platelet aggregation is dependent on platelet count in patients with coronary disease. Thromb Res 2012; 129: 56-61
  9. Rubak P, Villadsen K, Hvas AM. Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb Res 2012; 130: 420-3
  10. Taylor JE, Henderson IS, Stewart WK, Belch JJ. Platelet aggregation in erythropoietin treated dialysis patients. Platelets 1992; 3: 47-52
  11. Malyszko J, Suchowierska E, Pawlak K, Malyszko JS, Mysliwiec M. [Platelet aggregation and P-selectin concentration in patients on peritoneal dialysis treatedwith erythropoietin]. Pol Arch Med Wewn 2001; 105: 197-201
  12. Coleman JR, Moore EE, Kelher MR, Samuels JM, Cohen MJ, Sauaia A, et al. Female platelets have distinct functional activity compared to male platelets: Implications in transfusion practice and treatment of trauma-induced coagulopathy. J Trauma Acute Care Surg 2019; 87: 1052-60
  13. Gambardella L, Vona R, Pichini S, Pacifici R, Malorni W, Straface E. Gender difference in platelet aggregation and reactivity induced by recombinant human erythropoietin. Br J Clin Pharmacol 2016; 81: 789-91
  14. Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, et al. Impact of age on management and outcome of acute coronary syndrom